 |
13 Diseases |  |
0 Trials |
|
0 Trials |  |
21 News |  |
- | Pelubi (pelubiprofen) / Daiichi Sankyo, Daewon Pharma
Preclinical, Journal: Antinociceptive and anti-inflammatory activity of DW-1021, the ionic complex of pelubiprofen and tramadol, in rodents. (Pubmed Central) - May 29, 2023
In the carrageenan-induced rats, DW-1021 had a more potent effect on reducing paw inflammation (paw volume, width, and thickness) via the suppression of PGE production than tramadol, but less than that of pelubiprofen. Taken together, our results suggest that the administration of DW-1021, a combination of pelubiprofen and tramadol, exerted a potent effect and can be used as a potential therapeutic agent for relieving pain and inflammation.
- || Pelubi (pelubiprofen) / Daiichi Sankyo, Daewon Pharma
PK/PD data, Journal: Pharmacokinetic and Pharmacodynamic Characteristics of Pelubiprofen Tromethamine vs. Pelubiprofen in Healthy Subjects. (Pubmed Central) - Apr 28, 2023
The maximum cyclooxygenase-2 inhibitory effect of 25 mg of pelubiprofen tromethamine was approximately 98% compared to the reference, showing no significant pharmacodynamic variation. It is thus predicted that 25 mg of pelubiprofen tromethamine would show no clinically significant discrepancies in clinical analgesic and antipyretic effects from 30 mg of pelubiprofen.
- || Pelubi (pelubiprofen) / Daiichi Sankyo, Daewon Pharma
Clinical, Journal: Development of Pelubiprofen Tromethamine with Improved Gastrointestinal Safety and Absorption. (Pubmed Central) - Jun 3, 2021
The pharmacokinetic study of the PEL-T powder showed higher maximum plasma concentration (C) and area under the plasma concentration-time curve from 0 h to the last time point (AUC) than those of the PEL powder. Taken together, our data suggest that PEL-T is a recommendable candidate with enhanced gastrointestinal safety and better absorption compared with commercial PEL.
- | Pelubi (pelubiprofen) / Daiichi Sankyo, Daewon Pharmaceutical
Biomarker, Journal: XXYLT1 methylation contributes to the occurrence of lung adenocarcinoma: Methylation and lung adenocarcinoma. (Pubmed Central) - Jan 26, 2021
Taken together, our data suggest that PEL-T is a recommendable candidate with enhanced gastrointestinal safety and better absorption compared with commercial PEL. Our results suggested that methylation of XXYLT1 may have significance in the pathogenesis of lung adenocarcinoma.
- || Pelubi (pelubiprofen) / Daiichi Sankyo, Daewon Pharmaceutical
Clinical, Journal: Identification of nsSNPs of transcription factor E2F1 predisposing individuals to lung cancer and head and neck cancer. (Pubmed Central) - Dec 16, 2020
Statistical analysis showed that the mutant alleles/genotypes of rs3213172 (R252H) were found to increase ∼ 2-5 fold risk of LC and HNC in all the genetic models. These results suggest that the rs3213172C/T polymorphism of the E2F1 gene could be used as an effective biomarker for genetic susceptibility to LC and HNC in our population.
- || Pelubi CR (pelubiprofen controlled release) / Daewon Pharma, Pelubi (pelubiprofen) / Daiichi Sankyo, Daewon Pharmaceutical
Clinical, P4 data, Clinical Trial,Phase IV, Journal, Head-to-Head: Efficacy and safety of short-term use of a pelubiprofen CR and aceclofenac in patients with symptomatic knee osteoarthritis: A double-blinded, randomized, multicenter, active drug comparative, parallel-group, phase IV, non-inferiority clinical trial. (Pubmed Central) - Oct 28, 2020
These results suggest that the rs3213172C/T polymorphism of the E2F1 gene could be used as an effective biomarker for genetic susceptibility to LC and HNC in our population. Pelubiprofen CR 90 mg is as effective as aceclofenac 200 mg with reduced adverse events for the treatment of symptomatic knee osteoarthritis.
- || Pelubi (pelubiprofen) / Daiichi Sankyo, Daewon Pharmaceutical
Clinical, Journal: Machine learning in prediction of genetic risk of nonsyndromic oral clefts in the Brazilian population. (Pubmed Central) - Jul 5, 2020
Pelubiprofen CR 90 mg is as effective as aceclofenac 200 mg with reduced adverse events for the treatment of symptomatic knee osteoarthritis. Although validation is necessary, this genetic panel can be useful in the near future to assist in NSCL ± P genetic counseling.
- Pelubi (pelubiprofen) / Daiichi Sankyo, Daewon Pharmaceutical
[VIRTUAL] Genome-wide association analysis in host genetic characteristics of progression to high-grade cervical intraepithelial neoplasia or higher for women with human papillomavirus infection and normal cytology. (Poster Board 204) - Feb 27, 2020 - Abstract #ASCO2020ASCO_595;
These panels could be further tested in other ethnic populations. Research Funding: Supported by grants from Chang Gung Medical Foundation (OMRPG3B0041, CMRPG371151-3, CMRPG380731, CMRPG391451, and CRRPG3D0021/2/3), and the Ministry of Health and Welfare-Taiwan (DOHW105-TDU-B-212-113003, MOHW106-TDU-B-212-113005, and MOHW107-TDU-B-212-11
- | cytarabine / generics
Clinical, Journal: Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML). (Pubmed Central) - Jun 22, 2019
Research Funding: Supported by grants from Chang Gung Medical Foundation (OMRPG3B0041, CMRPG371151-3, CMRPG380731, CMRPG391451, and CRRPG3D0021/2/3), and the Ministry of Health and Welfare-Taiwan (DOHW105-TDU-B-212-113003, MOHW106-TDU-B-212-113005, and MOHW107-TDU-B-212-11 Data from our study demonstrated that SNPs in Ara-C and dNTP metabolic pathway predict chemosensitivity and prognosis of AML patients in China.
- ||||||| Pelubi (pelubiprofen) / Daiichi Sankyo, Daewon Pharma
Trial completion, Trial primary completion date: Phase 3 Study of Pelubiprofen & Loxoprofen in Patients With Upper Respiratory Tract Infection (clinicaltrials.gov) - Oct 11, 2016
P3, N=183, Completed, Sponsor: Daewon Pharmaceutical Co., Ltd.
Data from our study demonstrated that SNPs in Ara-C and dNTP metabolic pathway predict chemosensitivity and prognosis of AML patients in China. Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Mar 2016
- Pelubi (pelubiprofen) / Daiichi Sankyo, Daewon Pharma
Trial primary completion date: Phase 3 Study of Pelubiprofen & Loxoprofen in Patients With Upper Respiratory Tract Infection (clinicaltrials.gov) - Apr 15, 2015
P3, N=0, Recruiting, Sponsor: Daewon Pharmaceutical Co., Ltd.
Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Mar 2016 Trial primary completion date: Jun 2014 --> Jun 2016
- |||||||||| Pelubi CR (pelubiprofen controlled release) / Daewon Pharma, Pelubi (pelubiprofen) / Daiichi Sankyo, Daewon Pharma
New P3 trial: Phase 3 Study of DW-330SR2 and Pelubiprofen in Chronic Back Pain Patients (clinicaltrials.gov) - Mar 2, 2015
P3, N=166, Completed, Sponsor: Daewon Pharmaceutical Co., Ltd.
- Pelubi (pelubiprofen) / Daiichi Sankyo, Daewon Pharma
Enrollment open: Phase 3 Study of Pelubiprofen & Loxoprofen in Patients With Upper Respiratory Tract Infection (clinicaltrials.gov) - Feb 18, 2013
P3, N=0, Recruiting, Sponsor: Daewon Pharmaceutical Co., Ltd.
Trial primary completion date: Jun 2014 --> Jun 2016 Not yet recruiting --> Recruiting
- |||||||||| Pelubi (pelubiprofen) / Daiichi Sankyo, Daewon Pharma
New P3 trial: Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients (clinicaltrials.gov) - Jan 30, 2013
P3, N=120, Completed, Sponsor: Daewon Pharmaceutical Co., Ltd.
- | Pelubi (pelubiprofen) / Daiichi Sankyo, Daewon Pharma
New P3 trial: Phase 3 Study of Pelubiprofen & Loxoprofen in Patients With Upper Respiratory Tract Infection (clinicaltrials.gov) - Jan 28, 2013
P3, N=0, Recruiting, Sponsor: Daewon Pharmaceutical Co., Ltd.